Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.10 is 109% below its 5-year average of 1.11, around the middle of its 5-year range (-35.70–18.23).
As of the fiscal period ended Tuesday, June 30, 2026. 103.42% below its 12-month average of 2.95.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.10.
DEBT TO EQUITY RATIO
-0.10
DEBT TO EQUITY RATIO AVG TTM
2.95
DEBT TO EQUITY RATIO AVG 3Y
0.46
DEBT TO EQUITY RATIO AVG 5Y
1.11
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-103.42%
CURRENT VS 3Y AVG
-121.74%
CURRENT VS 5Y AVG
-109.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-191.65%
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.37B
Debt to Equity Ratio
-0.10
TTM Avg
2.95
3Y Avg
0.46
5Y Avg
1.11
Market Cap
$1.39B
Debt to Equity Ratio
0.01
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Debt to Equity Ratio
1.38
TTM Avg
1.15
3Y Avg
1.84
5Y Avg
2.31
Market Cap
$1.41B
Debt to Equity Ratio
0.14
TTM Avg
0.47
3Y Avg
16.23
5Y Avg
10.93
Market Cap
$1.33B
Debt to Equity Ratio
0.00
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.31B
Debt to Equity Ratio
0.34
TTM Avg
0.19
3Y Avg
0.15
5Y Avg
0.15
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.37B | -0.10 | 2.95 | 0.46 | 1.11 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | 0.01 | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 1.38 | 1.15 | 1.84 | 2.31 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | N/A | 9.31 | 9.31 | 6.28 |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | 0.14 | 0.47 | 16.23 | 10.93 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | 0.00 | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 25.47 | 2.79 | 1.47 | 0.99 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | 0.34 | 0.19 | 0.15 | 0.15 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | 0.16 | 0.12 | 0.09 |
Debt/Equity
-0.10
Current Ratio
5.07
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.10 |
| 2026-03-31 | -0.28 |
| 2025-12-31 | 13.39 |
| 2025-09-30 | 0.19 |
| 2025-06-30 | 1.56 |
| 2025-03-31 | 1.13 |
| 2024-12-31 | 0.06 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | 0.01 |
| 2024-03-31 | 18.23 |
| 2023-12-31 | 4.83 |
| 2023-09-30 | 1.60 |
| 2023-06-30 | -8.41 |
| 2023-03-31 | 13.61 |
| 2022-12-31 | 3.57 |
| 2022-09-30 | -4.93 |
| 2022-06-30 | -35.70 |
| 2022-03-31 | 4.22 |
| 2021-12-31 | 1.38 |
| 2021-09-30 | 2.74 |
| 2021-06-30 | 1.74 |
| 2021-03-31 | 0.62 |
| 2020-12-31 | 0.50 |
| 2020-09-30 | 0.20 |
| 2020-06-30 | -0.56 |
| 2020-03-31 | -0.75 |
| 2019-12-31 | -0.45 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | -0.68 |
| 2019-03-31 | -0.27 |
| 2018-12-31 | -0.16 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | -0.51 |
